Metabolic Abnormalities in Children With Epilepsy

NCT00001325 | Completed

• 2 other identifiers: 92017592-N-0175
• Study Type: observational
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

This study is designed to use positron emission tomography to measure brain energy use. Positron Emission Tomography (PET) is a technique used to investigate the functional activity of the brain. The PET technique allows doctors to study the normal processes of the brain (central nervous system) of normal individuals and patients with neurologic illnesses without physical / structural damage to the brain. When a region of the brain is active, it uses more fuel in the form of oxygen and sugar (glucose). As the brain uses more fuel it produces more waste products, carbon dioxide and water. Blood carries fuel to the brain and waste products away from the brain. As brain activity increases blood flow to and from the area of activity increases also. Researchers can label a sugar with a small radioactive molecule called FDG (fluorodeoxyglucose). As areas of the brain use more sugar the PET scan will detect the FDG and show the areas of the brain that are active. By using this technique researchers hope to answer the following questions; 4\. Are changes in brain energy use (metabolism) present early in the course of epilepsy 5\. Do changes in brain metabolism match the severity of patient's seizures 6\. Do changes in metabolism occur over time or in response to drug therapy

Conditions

Generalized Epilepsy; Infantile Spasms; Metabolic Disease; Partial Epilepsy; Seizures

Keywords

Positron; Tomography; Seizures; Epileptic Focus; Electroencephalography; Metabolism; Glucose; Cerebral; Positron Emission Tomography; Lennox Gastaut Syndrome

Interventions

18 FDG DRUG

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients with partial seizures, infantile spasms and Lennox-Gastaut syndrome will be selected.

You may not qualify if:

• Evidence of a structural lesion as cause for epilepsy.
• Degenerative or metabolic disease.
• Inability to comply with the protocol.

Sponsors & Collaborators

• National Institute of Neurological Disorders and Stroke (NINDS): lead

Study Sites (1)

National Institute of Neurological Disorders and Stroke (NINDS)

Bethesda, Maryland, 20892, United States

Location

Related Publications (3)

• Bourgeois BF, Prensky AL, Palkes HS, Talent BK, Busch SG. Intelligence in epilepsy: a prospective study in children. Ann Neurol. 1983 Oct;14(4):438-44. doi: 10.1002/ana.410140407.

  PMID: 6416142 BACKGROUND

• Chugani HT, Phelps ME, Mazziotta JC. Positron emission tomography study of human brain functional development. Ann Neurol. 1987 Oct;22(4):487-97. doi: 10.1002/ana.410220408.

  PMID: 3501693 BACKGROUND

• Engel J Jr, Kuhl DE, Phelps ME, Mazziotta JC. Interictal cerebral glucose metabolism in partial epilepsy and its relation to EEG changes. Ann Neurol. 1982 Dec;12(6):510-7. doi: 10.1002/ana.410120603.

  PMID: 6818896 BACKGROUND

MeSH Terms

Conditions

Epilepsy, Generalized; Spasms, Infantile; Metabolic Diseases; Epilepsies, Partial; Seizures; Lennox Gastaut Syndrome

Interventions

Fluorodeoxyglucose F18

Condition Hierarchy (Ancestors)

Epilepsy; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Epileptic Syndromes; Nutritional and Metabolic Diseases; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Intervention Hierarchy (Ancestors)

Deoxyglucose; Deoxy Sugars; Carbohydrates

Study Design

• Study Type: observational
• Sponsor Type: NIH

Study Record Dates

• First Submitted: November 3, 1999
• First Posted: November 4, 1999
• Study Start: April 1, 1992
• Study Completion: June 1, 2004
• Last Updated: March 4, 2008

Record last verified: 2004-06

Locations

US (1)